Assetmark, Inc Cellectis S.A. Transaction History

Assetmark, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$1.72 - $2.12 $1,393 - $1,717	810 Added 42.39%	2,721 $5,000
Q1 2023 May 05, 2023	BUY	$1.83 - $3.84 $715 - $1,501	391 Added 25.72%	1,911 $3,000
Q4 2022 Feb 10, 2023	BUY	$1.85 - $2.6 $703 - $988	380 Added 33.33%	1,520 $3,000
Q3 2022 Nov 01, 2022	BUY	$2.29 - $4.08 $629 - $1,122	275 Added 31.79%	1,140 $3,000
Q2 2022 Aug 03, 2022	BUY	$2.39 - $4.93 $1,206 - $2,489	505 Added 140.28%	865 $2,000
Q1 2022 May 13, 2022	BUY	$3.45 - $8.77 $1,242 - $3,157	360 New	360 $2,000

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.